Statin drugs may do more harm than good, article claims

13 June 2014

"Statins," already the most prescribed drugs in history, are being recommended for more and more patients as "primary prevention" for cardiovascular disease. Nearly 900 studies have been published on the adverse effects of these medications, and a look at their mechanism of action suggests ample reason for caution. Neurospecialist and pharmacologist Timothy Marshall, discusses the controversy in the summer issue of the Journal of American Physicians and Surgeons.

"Massive corporate-funded campaigns have further promoted the idea that cholesterol...is an enemy to be avoided, or at the very least, minimized at all costs," Dr Marshall writes. In fact, "it is a vital and essential nutrient," he noted.

Several recent studies have shown that lower serum cholesterol levels are associated with a lower survival rate (increased mortality). Cholesterol is needed for proper immune system function, the synthesis of steroid hormones, and the integrity of the nervous system. The body needs adequate cholesterol levels to make vitamin D, which has anti-cancer activity and many other health-promoting functions, the article states.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical